成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 144143-96-4 Chemical Structure| 144143-96-4
Chemical Structure| 144143-96-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 144143-96-4

,{[proInfo.pro_purity]}

Eprosartan Mesylate is a reversible and competitive angiotensin II receptor inhibitor.

Synonyms: SKF-108566J; Eprosartan (mesylate); SKF-108566

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Eprosartan mesylate

CAS No. :144143-96-4
Formula : C24H28N2O7S2
M.W : 520.62
SMILES Code : O=C(O)C1=CC=C(CN2C(/C=C(C(O)=O)\CC3=CC=CS3)=CN=C2CCCC)C=C1.CS(=O)(O)=O
Synonyms :
SKF-108566J; Eprosartan (mesylate); SKF-108566
MDL No. :MFCD08141807
InChI Key :DJSLTDBPKHORNY-XMMWENQYSA-N
Pubchem ID :5282474

Safety of Eprosartan mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Related Pathways of Eprosartan mesylate

GPCR

Isoform Comparison

Biological Activity

Target
  • AT1 receptor

    AT1 receptor, Kd:0.83 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01715584 Hypertension Phase 4 Recruiting December 31, 2019 Canada, Ontario ... More >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD ?? 519 685 8500 ext 58525 ?? Craig.Railton@lhsc.on.ca ?? Principal Investigator: Craig J Railton, MD, PhD ?? ?? ?? Sub-Investigator: Jonathan Fairbairn, BSc ?? ?? ?? Sub-Investigator: George Nicoloau, MD ?? ?? ?? Sub-Investigator: Robert Gros, PhD ?? ?? ?? Sub-Investigator: Jason Franklin, MD ?? ?? ?? Sub-Investigator: John Yoo, MD ?? ?? ?? Sub-Investigator: Kevin Fung, MD ?? ?? ?? Sub-Investigator: Anthony Nichols, MD ?? ?? ?? Sub-Investigator: Danielle McNeil, MD Less <<
NCT02024100 - Unknown December 2016 Korea, Republic of ... More >> Seoul National University Bundang Hospital Recruiting Seongnam-si, Bundang-gu, Korea, Republic of, 463-717 Contact: Chang Hwan Yoon, MD ?? ?? ?? Principal Investigator: Chang Hwan Yoon, MD Less <<
NCT01753206 - Completed - Korea, Republic of ... More >> Seoul National University Bundang Hospital Seongnam-si, Bundang-gu, Korea, Republic of, 463-717 Less <<
NCT01087749 Kidney Disease Phase 1 Completed - United States, California ... More >> Clinical Reserach Center, UCSF San Francisco,, California, United States, 94143 Less <<
NCT01631227 - Completed - -
NCT01631227 Essential Hypertension Phase 3 Completed - Germany ... More >> Site Reference ID/Investigator# 74062 Berlin, Germany, 12627 Site Reference ID/Investigator# 74066 Bochum, Germany, 44787 Site Reference ID/Investigator# 74065 Dresden, Germany, 01067 Site Reference ID/Investigator# 93513 Dresden, Germany, 01307 Site Reference ID/Investigator# 93495 Essen, Germany, 45355 Site Reference ID/Investigator# 93515 Frankfurt, Germany, 60594 Site Reference ID/Investigator# 74060 Frankfurt, Germany, 60596 Site Reference ID/Investigator# 74063 Goerlitz, Germany, 02826 Site Reference ID/Investigator# 93494 Hamburg, Germany, 22143 Site Reference ID/Investigator# 93493 Karlsruhe, Germany, 76199 Site Reference ID/Investigator# 74061 Leipzig, Germany, 04103 Site Reference ID/Investigator# 74064 Magdeburg, Germany, 39104 Site Reference ID/Investigator# 93514 Nuremberg, Germany, 90402 Russian Federation Site reference ID/Investigator # 82515 Barnaul, Russian Federation, 656055 Site reference ID/Investigator # 82520 Kazan, Russian Federation, 420012 Site reference ID/Investigator # 82493 Kemerovo, Russian Federation, 650002 Site reference ID/Investigator # 82516 Kemerovo, Russian Federation, 650055 Site refernce ID/Investigator # 82521 Krasnodar, Russian Federation, 350086 Site reference ID/Investigator # 82495 Novosibirsk, Russian Federation, 630008 Site reference ID/Investigator # 82494 Novosibirsk, Russian Federation, 630047 Site reference ID/Investigator # 82525 Novosibirsk, Russian Federation, 630068 Site reference ID/Investigator # 82522 St. Petersburg, Russian Federation, 192283 Site reference ID/Investigator # 82517 St. Petersburg, Russian Federation, 194044 Site reference ID/Investigator # 82524 St. Petersburg, Russian Federation, 197022 Site reference ID/Investiragor # 82523 St. Petersburg, Russian Federation, 197022 Site reference ID/Investigator # 82519 St. Petersburg, Russian Federation, 198205 Site reference ID/Investigator # 82518 St. Petersburg, Russian Federation, 198260 Site reference ID/Investigator # 82527 St. Petersburg, Russian Federation, 199106 United Kingdom Site Reference ID/Investigator# 74057 Birmingham, United Kingdom, B15 2SQ Site Reference ID/Investigator# 74059 Cardiff, United Kingdom, CF14 5GJ Site Reference ID/Investigator# 74056 Chorley, United Kingdom, PR7 7NA Site Reference ID/Investigator# 74054 Glasgow, United Kingdom, G20 0SP Site reference ID/Investigator # 95456 Glasgow, United Kingdom, G45 9AW Site Reference ID/Investigator# 74053 Liverpool, United Kingdom, L22 0LG Site reference ID/Investigator # 95457 London, United Kingdom, EC1M 6BQ Site Reference ID/Investigator# 74055 Manchester, United Kingdom, M16 6SX Site reference ID/Investigator # 95455 Northwood, United Kingdom, HA6 2RN Site Reference ID/Investigator# 74058 Reading, United Kingdom, RG2 0TG Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.60mL

1.92mL

0.96mL

19.21mL

3.84mL

1.92mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories